Furey Raymond J. 4

What Happened
Raymond J. Furey, EVP, General Counsel, Chief Compliance Officer and Corporate Secretary of Rigel Pharmaceuticals, received an award of 19,497 restricted stock units (RSUs) on February 17, 2026. The RSUs were recorded at $0.00 per share (no cash paid). The total grant is 19,497 shares that will convert to common stock as they vest; this is an award/compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-02-17 (Form 4 filed 2026-02-19). Filing appears within the typical two-business-day reporting window.
• Amount: 19,497 RSUs; reported price $0.00 (award).
• Vesting: RSUs vest quarterly over three years; first quarterly vesting on March 31, 2026 (footnote F1).
• Shares owned after the transaction: not specified in the information provided.
• No 10b5-1 plan, tax-withholding sale, or other special codes are noted in the provided details.

Context
RSUs are a common form of executive compensation; they do not require an upfront purchase and only convert into shares as they vest. Such grants are routine for employee retention and compensation and are different from open-market purchases (which can be interpreted as a stronger bullish signal). The grant itself does not by itself indicate the insider’s trading intent.